StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) stock

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Oncotelic Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Oncotelic Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2024 was $12.21K. For fiscal 2025 it was $4.36K, down 92.9% from the year before. Over ten years it grew -52.5% a year on average. The highest annual figure on record is $22.26M in fiscal 2009.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.36K-92.9%
FY2023Dec 31, 2023$61.14K-91.9%
FY2022Dec 31, 2022$756.91K-79.3%
FY2021Dec 31, 2021$3.66M-15.0%
FY2020Dec 31, 2020$4.30M+213.6%
FY2019Dec 31, 2019$1.37M+111.2%
FY2018Dec 31, 2018$649.76K-93.8%
FY2017Dec 31, 2017$10.47M+19.5%
FY2016Dec 31, 2016$8.76M-3.5%
FY2015Dec 31, 2015$9.09M+22.7%
FY2014Dec 31, 2014$7.41M+103.7%
FY2013Dec 31, 2013$3.64M+3.2%
FY2012Dec 31, 2012$3.52M-33.4%
FY2011Dec 31, 2011$5.29M-56.3%
FY2010Dec 31, 2010$12.11M-45.6%
FY2009Dec 31, 2009$22.26M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$345-28.1%
Q1 FY2026Mar 31, 2026$795+215.5%
Q2 FY2025Jun 30, 2025$297-38.1%
Q1 FY2025Mar 31, 2025$297-97.3%
Q3 FY2024Sep 30, 2024$480-97.7%
Q2 FY2024Jun 30, 2024$252-99.6%
Q1 FY2024Mar 31, 2024$480-99.3%
Q4 FY2023Dec 31, 2023$11.00K+546.8%
Q3 FY2023Sep 30, 2023$21.22K-80.5%
Q1 FY2023Mar 31, 2023$65.92K-88.6%
Q4 FY2022Dec 31, 2022$66.21K-87.3%
Q3 FY2022Sep 30, 2022$1.70K-99.7%
Q2 FY2022Jun 30, 2022$108.71K-88.6%
Q1 FY2022Mar 31, 2022$580.30K-62.7%
Q4 FY2021Dec 31, 2021$523.20K-79.7%
Q3 FY2021Sep 30, 2021$621.93K-33.6%
Q2 FY2021Jun 30, 2021$956.81K+98.5%
Q1 FY2021Mar 31, 2021$1.56M+398.9%
Q4 FY2020Dec 31, 2020$2.57M+877.6%
Q3 FY2020Sep 30, 2020$936.20K+172.3%
Q2 FY2020Jun 30, 2020$482.14K+32.5%
Q1 FY2020Mar 31, 2020$312.00K-22.9%
Q4 FY2019Dec 31, 2019$263.10K-8.2%
Q3 FY2019Sep 30, 2019$343.79K+160.9%
Q2 FY2019Jun 30, 2019$363.77K+263.6%
Q1 FY2019Mar 31, 2019$404.85K+79.9%
Q4 FY2018Dec 31, 2018$286.62K-83.8%
Q3 FY2018Sep 30, 2018$131.75K-95.3%
Q2 FY2018Jun 30, 2018$100.05K-96.7%
Q1 FY2018Mar 31, 2018$225.00K-92.1%
Q4 FY2017Dec 31, 2017$1.77M-24.1%
Q3 FY2017Sep 30, 2017$2.83M+36.5%
Q2 FY2017Jun 30, 2017$3.02M+27.2%
Q1 FY2017Mar 31, 2017$2.85M–
Q4 FY2016Dec 31, 2016$2.34M–
Q3 FY2016Sep 30, 2016$2.08M–
Q2 FY2016Jun 30, 2016$2.37M–

More Oncotelic Therapeutics figures

See a number that looks wrong?